GH, CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究调查了腹部脂肪水平高、生长激素(GH)水平低的女性。这项研究的目的是调查生长激素替代疗法是否能减少这一人群的腹部脂肪。由于腹部脂肪与心脏病风险的增加有关，我们也在研究生长激素替代疗法是否降低了这一人群的心脏病风险。 具体目标--将检验以下假设： 具体目标1：内脏肥胖症女性生长激素(GH)分泌减少，这与心血管风险增加有关。 我们将调查患有内脏肥胖症的女性是否： 答：与1)正常体重女性和2)没有内脏肥胖症的BMI匹配的女性相比，生长激素分泌减少 生长激素分泌减少与心血管风险标记物的增加有关。 具体目标2：对患有内脏肥胖症和相对生长激素缺乏的女性服用低剂量重组生长激素6个月将导致内脏脂肪减少和心血管风险标志物的改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study examines women who have both high levels of belly fat and low levels of growth hormone (GH). The purpose of the study is to investigate whether GH replacement therapy reduces belly fat in this population. Since belly fat is associated with an increased risk for heart disease, we are also studying whether GH replacement therapy reduces the risk of heart disease in this population. Specific Aims - The following hypotheses will be tested: Specific Aim 1: Women with visceral adiposity have reduce growth hormone (GH) secretion, which is associated with increased cardiovascular risk. We will investigate in women with visceral adiposity whether: A. Growth hormone secretion is reduced compared with 1) normal-weight women and 2) BMI-matched women who do not have visceral adiposity b. Reduced growth hormone secretion is associated with increases in cardiovascular risk markers. Specific Aim 2: Administration of low dose recombinant GH for six months to women with visceral adiposity and relative growth hormone deficiency will result in reduced visceral fat mass and improvements in markers of cardiovascular risk.